"Antiparkinson Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
| Descriptor ID |
D000978
|
| MeSH Number(s) |
D27.505.954.427.090.050
|
| Concept/Terms |
Antiparkinson Agents- Antiparkinson Agents
- Agents, Antiparkinson
- Antiparkinsonian Agents
- Agents, Antiparkinsonian
- Antiparkinsonians
- Antiparkinson Drugs
- Drugs, Antiparkinson
|
Below are MeSH descriptors whose meaning is more general than "Antiparkinson Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiparkinson Agents".
This graph shows the total number of publications written about "Antiparkinson Agents" by people in this website by year, and whether "Antiparkinson Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiparkinson Agents" by people in Profiles.
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
-
Executive function and dopamine response in Parkinson's disease freezing of gait. Parkinsonism Relat Disord. 2021 11; 92:46-50.
-
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
-
Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation. J Neurol Sci. 2018 07 15; 390:33-35.
-
Functional neurological disorders in Parkinson disease. J Neurol Neurosurg Psychiatry. 2018 06; 89(6):566-571.
-
Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 07; 205:93-98.
-
Flamenco dancer posture: Unique "off" complication in Parkinson disease. Neurology. 2016 04 12; 86(15):1462-1463.
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
-
Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
-
A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013; 35(1-2):1-22.